FDA Data Flags Ibogaine, Mitragynine Cardiac Risks in US Review

FDA Adverse Event Data Reveal Significant Cardiac Risks for Ibogaine and Mitragynine

Analysis of the FDA Adverse Event Reporting System (FAERS) from 2000 to 2024 demonstrates that ibogaine and mitragynine are associated with a disproportionately high risk of ventricular arrhythmia and QTc prolongation. According to the study published on September 10, 2026 (OpenAlex W7212120531), these substances showed proportional reporting ratios (PRR) for arrhythmia and cardiac arrest that were comparable to or exceeded those of established proarrhythmic drugs such as dofetilide and methadone. Specifically, ibogaine exhibited a PRR of 142.0 for ventricular arrhythmia, approximately six times higher than dofetilide, while mitragynine also showed elevated signals (PRR 4.4 for arrhythmia, PRR 15.9 for QTc prolongation).

These findings are based on 61,961 FAERS reports mentioning psychoactive drugs, out of 18.5 million unique cases. The analysis included both Schedule I substances and unscheduled compounds with therapeutic interest, such as ibogaine, mitragynine (the main alkaloid in kratom), MDMA (3,4-methylenedioxy-methamphetamine), LSD (lysergic acid diethylamide), and others.

Mechanisms, Clinical Context, and Regulatory Landscape

Ibogaine and mitragynine are linked to cardiac arrhythmias primarily through their effects on cardiac ion channels, notably by blocking the hERG (human Ether-à-go-go-Related Gene) potassium channel, leading to QT interval prolongation. QTc prolongation increases the risk of torsades de pointes, a potentially fatal ventricular tachyarrhythmia. While this mechanism is well-characterized for ibogaine, the new data quantifies the risk in real-world settings and highlights mitragynine's previously underappreciated proarrhythmic potential.

These findings arrive as federal agencies, under a recent executive order, are accelerating psychedelic drug development and facilitating access through increased funding and expedited FDA review. Ibogaine is being investigated for opioid use disorder, while mitragynine is widely consumed in the form of kratom, which remains legal in some states and banned in others. The study's use of dofetilide (a known proarrhythmic antiarrhythmic drug) and naltrexone (a negative control) as comparators strengthens the clinical relevance of the safety signals detected.

Policy, Research, and Clinical Implications

The robust association between ibogaine, mitragynine, and cardiac arrhythmia is likely to prompt regulatory agencies such as the FDA to impose stricter cardiac safety requirements in clinical trials and expanded access programs. Sponsors can expect enhanced cardiac monitoring (e.g., serial ECGs, telemetry), exclusion criteria for patients with preexisting cardiac risk factors, and potentially mandatory risk evaluation and mitigation strategies (REMS) for any approved products.

• For ibogaine, which has been used in unregulated addiction treatment settings, the findings may lead to increased scrutiny of underground or offshore clinics and renewed calls for standardized protocols and medical oversight.
• For mitragynine and kratom products, which are widely available online and in retail outlets, the data may influence ongoing federal and state-level scheduling debates and could prompt new warnings or restrictions.
• Trial sponsors and investigators will need to justify their cardiac safety monitoring plans in regulatory submissions and may face higher barriers to entry for at-risk populations.

A less-discussed but critical implication is that these safety signals could affect the design of real-world evidence studies and post-marketing surveillance, as spontaneous reporting systems like FAERS may underreport or misclassify events, especially in unscheduled or illicit drug use contexts.

Risks, Limitations, and Remaining Unknowns

While the FAERS database provides valuable pharmacovigilance signals, it is subject to underreporting, reporting bias, and lack of denominator data (i.e., true exposure rates). The observed PRRs indicate disproportionate reporting, not absolute risk, and may be influenced by heightened awareness or severe outcomes prompting more frequent reporting.

The clinical translation of these findings requires context: ibogaine's use is largely limited to specialized or unregulated settings, while mitragynine's widespread availability may mask the true incidence of adverse events. Notably, the analysis found no significant arrhythmia signal for LSD, mescaline, or psilocybin, suggesting that cardiac risk is not a class effect among psychedelics but rather substance-specific.

Unanswered questions include the dose-response relationship, the impact of polypharmacy, and the role of genetic or comorbid risk factors. Future studies should integrate prospective ECG monitoring and mechanistic investigations to clarify causality and refine risk stratification.

Looking Forward: Regulatory and Industry Outlook

The identification of strong cardiac safety signals for ibogaine and mitragynine is poised to shape the next phase of psychedelic drug development in the United States. As federal agencies move to accelerate access, rigorous cardiac risk management will become a non-negotiable element of both clinical trials and eventual clinical use. Stakeholders—from trial sponsors to clinicians and public health authorities—should anticipate evolving guidance on cardiac screening, monitoring, and exclusion, as well as possible REMS requirements for any approved products.

For the emerging psychedelic industry, these findings underscore the need for transparent risk communication, robust safety protocols, and proactive engagement with regulators. The path to clinical adoption will depend not only on demonstrating efficacy but also on addressing the nuanced and sometimes substance-specific safety profiles revealed by large-scale real-world data.

How we research: This article was written by Dr. Alex R. Miller, MD, MPH. Reviewed by Dr. Miller on 2026-09-11. Primary source: OpenAlex W7212120531. FDA FAERS data and analysis as cited.